ストックスクリーナーアプリを入手
10.14
1.60%
0.16
アフターアワーズ：
10.00
-0.14
-1.38%
前日終値:
$9.98
開ける：
$10.17
24時間の取引高:
411.90K
Relative Volume:
1.21
時価総額：
$563.05M
収益：
-
当期純損益:
$-117.99M
株価収益率:
-4.739
EPS:
-2.1397
ネットキャッシュフロー:
$-79.92M
1週間 パフォーマンス:
-3.98%
1か月 パフォーマンス:
-23.12%
6か月 パフォーマンス:
-61.44%
1年 パフォーマンス:
-41.72%
1日の値動き範囲:
$9.67
$10.43
1週間の範囲:
$9.65
$10.84
52週間の値動き範囲:
$9.65
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
10.14 | 586.38M | 0 | -117.99M | -79.92M | -2.1397 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-19 | 開始されました | JP Morgan | Overweight |
| 2025-08-27 | 開始されました | Needham | Buy |
| 2023-12-05 | 開始されました | Chardan Capital Markets | Buy |
| 2023-10-05 | 開始されました | Stifel | Buy |
| 2023-06-14 | 開始されました | BofA Securities | Buy |
| 2023-06-12 | 開始されました | H.C. Wainwright | Buy |
| 2023-06-08 | 開始されました | Robert W. Baird | Outperform |
| 2023-05-10 | 開始されました | Pareto | Buy |
| 2023-04-28 | 開始されました | Wedbush | Outperform |
すべてを表示
Oculis Holding Ag (OCS) 最新ニュース
Oculis Holding AG Ordinary shares (NASDAQ: OCS) Share Price, OCS Stock News, OCS Share Price & Updates - Kalkine
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade - qz.com
Precision Trading with Oculis Holding Ag (OCS) Risk Zones - Stock Traders Daily
Oculis doses first patient in phase 3 privosegtor trial for ON - Glance by Eyes On Eyecare
Oculis Holding - The Pharma Letter
H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com
There Is No Approved Specific Treatment for Acute Optic Neuritis. Oculis Is Testing One. - stocktitan.net
Enterprise value to revenue forward of Oculis Holding AG – FWB:CR5 - TradingView
Oculis (OCS) Daily Review: Rises 0.38% to $13.19 at the Close; Chart Reference: $12.53 and $13.85 Define the Nearby Reference Levels for the Current SessionAnchored VWAP - vinanet.vn
Oculis (OCSAW) Session-Level Review: Ends Up by 6.00% at $5.04 in the Latest Session; Current Setup: the Near-Term Reference Band Stretches From $4.79 to $5.29 in the Current UpdateAggressive Growth Picks - vinanet.vn
Oculis Holding (OCS) Advances 0.94% as Shares Hold Above Key SupportDouble Top - vinanet.vn
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com Nigeria
The Technical Signals Behind (OCS) That Institutions Follow - Stock Traders Daily
Four Oculis directors' restricted stock units vest in Aug. 13 notifications - Stock Titan
Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Zacks Investment Research
Stifel reiterates Buy rating on Oculis stock, $40 target - Investing.com
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation Range NarrowsVolatility Breakout Picks - Vinanet
Oculis buys out privosegtor’s global rights from Accure - Glance by Eyes On Eyecare
HC Wainwright Has Negative Estimate for Oculis Q3 Earnings - MarketBeat
Oculis rebuilds pipeline with Privosegtor buy from Accure - AllSci
Oculis Holding AG (OCS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oculis Announces Asset Purchase Agreement With Accure Therapeutics, Posts Q2 2026 Financial Results - VisionMonday.com
Oculis Holding (OCS) inks $3.8M cash-plus-shares deal for Privosegtor rights - Stock Titan
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company - The Manila Times
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, ... - pmg-ky3.com
Oculis to buy Accure rights to Privosegtor for $3.8 million plus up to 2,050,000 shares - Bitget
Oculis acquires full rights to Privosegtor, boo... - Pluang
Oculis to Acquire Full Global Rights to Privosegtor from Accure Therapeutics in Strategic Asset Purchase - Quiver Quantitative
Oculis Signs Asset Purchase Agreement with Accure - GlobeNewswire
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation ContinuesSweep Order Flow - vinanet.vn
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results - MarketBeat
Oculis Holding AG (OCS) stock price, news, quote and history - Yahoo Finance UK
Oculis Holding earnings beat by CHF0.23, revenue topped estimates - Investing.com Nigeria
Wall Street Zen Upgrades Oculis (NASDAQ:OCS) to Sell - MarketBeat
Oculis Holding AG (OCS) Stock News Today - TradingKey
Oculis Holding AG (OCS) Stock Analysis: Navigating a 190.92% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Oculis Reports Q2 2026 Financial Results and Provides Company Update - The Manila Times
Oculis Holding AG Stock 12‑Month Price Target Cut to $36.26, Implies 193% Upside - TradingView
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Oculis Holding AG reports results for the quarter ended June 30Earnings Summary - TradingView
Oculis Q2 2026 Results: Finance Gains Narrow the Net Loss Despite Higher Costs - TradingKey
OCS: Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth - TradingView
Oculis (NASDAQ: OCS) pivots to neuro-ophthalmology as H1 loss falls - stocktitan.net
Oculis birtir uppgjör fyrir annan ársfjórðung 2026 og kynnir áfanga í rekstri félagsins - GlobeNewswire
Earnings To Watch: Oculis Holding AG (OCS) Reports Q2 2026 Result - Yahoo Finance
Oculis Receives Positive FDA Feedback for Privosegtor Development in Acute Multiple Sclerosis Relapses - Quiver Quantitative
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses - Yahoo Finance Singapore
Oculis Holding Ag (OCS) 財務データ
収益
当期純利益
現金流量
EPS
0.88%
大文字化:
|
ボリューム (24 時間):